These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24945879)

  • 1. Predicting mortality in HIV-infected children initiating highly active antiretroviral therapy in a resource-deprived setting.
    Nugent J; Edmonds A; Lusiama J; Thompson D; Behets F;
    Pediatr Infect Dis J; 2014 Nov; 33(11):1148-55. PubMed ID: 24945879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
    BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study.
    Edmonds A; Yotebieng M; Lusiama J; Matumona Y; Kitetele F; Napravnik S; Cole SR; Van Rie A; Behets F
    PLoS Med; 2011 Jun; 8(6):e1001044. PubMed ID: 21695087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India.
    Banerjee T; Pensi T; Banerjee D; Grover G
    Ann Trop Paediatr; 2010; 30(1):27-37. PubMed ID: 20196931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality and its predictors among highly active antiretroviral therapy naive hiv-infected individuals: data from prospective cohort study in Ukraine.
    Zhyvytsia D
    Georgian Med News; 2014; (232-233):69-74. PubMed ID: 25214276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy.
    Puthanakit T; Aurpibul L; Oberdorfer P; Akarathum N; Kanjananit S; Wannarit P; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2007 Feb; 44(4):599-604. PubMed ID: 17243067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S; Alary M
    HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of early mortality in a cohort of HIV-infected children receiving high active antiretroviral treatment in public hospitals in Ethiopia.
    Ebissa G; Deyessa N; Biadgilign S
    AIDS Care; 2015; 27(6):723-30. PubMed ID: 25599414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort.
    Wamalwa DC; Obimbo EM; Farquhar C; Richardson BA; Mbori-Ngacha DA; Inwani I; Benki-Nugent S; John-Stewart G
    BMC Pediatr; 2010 May; 10():33. PubMed ID: 20482796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality and associated factors after initiation of pediatric antiretroviral treatment in the Democratic Republic of the Congo.
    Callens SF; Shabani N; Lusiama J; Lelo P; Kitetele F; Colebunders R; Gizlice Z; Edmonds A; Van Rie A; Behets F;
    Pediatr Infect Dis J; 2009 Jan; 28(1):35-40. PubMed ID: 19057457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia.
    Bolton-Moore C; Mubiana-Mbewe M; Cantrell RA; Chintu N; Stringer EM; Chi BH; Sinkala M; Kankasa C; Wilson CM; Wilfert CM; Mwango A; Levy J; Abrams EJ; Bulterys M; Stringer JS
    JAMA; 2007 Oct; 298(16):1888-99. PubMed ID: 17954540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of mortality among HIV-infected children receiving highly active antiretroviral therapy.
    Njom Nlend AE; Loussikila AB
    Med Mal Infect; 2017 Feb; 47(1):32-37. PubMed ID: 27609595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings.
    Marazzi MC; Liotta G; Germano P; Guidotti G; Altan AD; Ceffa S; Lio MM; Nielsen-Saines K; Palombi L
    AIDS Res Hum Retroviruses; 2008 Apr; 24(4):555-60. PubMed ID: 18366314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
    Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
    J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.